

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
METHODOLOGY	2
ANALYST CREDENTIALS.....	2
RELATED BCC STUDIES	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
 CHAPTER TWO: SUMMARY.....	 4
GENETIC DISORDER MARKETS: MAJOR MARKETS SUMMARY	4
<i>SUMMARY TABLE A GLOBAL GENETIC DISORDER PRODUCT</i>	
<i>REVENUES BY MAJOR MARKET SEGMENT, THROUGH 2014 (\$</i>	
<i>MILLIONS)</i>	5
<i>SUMMARY FIGURE GLOBAL GENETIC DISORDER PRODUCT</i>	
<i>REVENUES, 2007-2014 (\$ MILLIONS)</i>	5
LEADING MANUFACTURERS	5
<i>SUMMARY TABLE B TOTAL COMPANY SALES FOR GENETIC</i>	
<i>DISORDER TREATMENT, 2009 (\$ MILLIONS)</i>	6
 CHAPTER THREE: INDUSTRY OVERVIEW.....	 7
INTRODUCTION	7
HISTORY OF GENETIC RESEARCH	7
OVERVIEW OF DNA AND GENES.....	7
THE HUMAN GENOME PROJECT.....	8
HAPMAP PROJECT	9
TERMINOLOGY.....	9
<i>TABLE 1 GLOSSARY OF GENETIC TERMS</i>	9
<i>TABLE 1 (CONTINUED)</i>	10
<i>TABLE 1 (CONTINUED)</i>	11
<i>TABLE 1 (CONTINUED)</i>	12
<i>TABLE 1 (CONTINUED)</i>	13
<i>TABLE 1 (CONTINUED)</i>	14
<i>TABLE 1 (CONTINUED)</i>	15
<i>TABLE 1 (CONTINUED)</i>	16
GENES AND FAMILY HISTORY	16
OVERVIEW OF GENETIC DISORDERS	16
GENE MUTATIONS.....	16
CAUSES OF GENE MUTATIONS.....	17
GENETIC TESTING AND SCREENING.....	18
TESTING POPULATION GROUPS (ETHNOGENETICS).....	19
DIRECT TO CONSUMER GENETIC TESTING	19
U.S. DEMOGRAPHICS	20
<i>TABLE 2 NUMBER OF BIRTHS IN THE U.S., 2006-2010</i>	21

<i>TABLE 3 POPULATION GROWTH AND BIRTH STATISTICS U.S., 2011-2020 (THOUSANDS)</i>	21
<i>FIGURE 1 POPULATION GROWTH AND BIRTH STATISTICS U.S. 2011-2020 (THOUSANDS)</i>	22
INTERNATIONAL DEMOGRAPHICS	23
<i>TABLE 4 ESTIMATED WORLD POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, 2000 THROUGH 2030 (MILLIONS)</i>	23
<i>FIGURE 2 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)</i>	23
<i>TABLE 5 WORLD POPULATION BY SELECTED COUNTRIES, THROUGH 2014 (MILLIONS)</i>	24
<i>FIGURE 3 WORLD POPULATION BY SELECTED COUNTRIES, 2007-2014 (MILLIONS)</i>	25
INTERNATIONAL BIRTH RATE STATISTICS.....	25
<i>TABLE 6 BIRTHS FOR SELECTED COUNTRIES, 1995-2015 (THOUSANDS)</i>	26
<i>FIGURE 4 BIRTHS FOR SELECTED COUNTRIES, 1995-2015 (THOUSANDS)</i>	26
CHAPTER FOUR: ISSUES AFFECTING THE MARKET.....	27
GENETIC RESEARCH	27
GENE THERAPY COMPARED TO CELL THERAPY	27
ISSUES WITH HUMAN CLONING.....	28
LEGISLATIVE ISSUES.....	28
THE GENETIC INFORMATION NONDISCRIMINATION ACT (GINA)	28
GERMAN LEGISLATION	29
AUSTRALIAN GENETIC TESTING LAW.....	29
EUROPEAN UNION ACTION IN THE FIELD OF RARE DISEASES.....	30
GENETICS CLINICS	30
<i>TABLE 7 NUMBER OF GENETIC CLINICS BY COUNTRY</i>	31
GENOME SEQUENCING TECHNOLOGY.....	31
TECHNOLOGICAL APPLICATIONS OF GENOME SEQUENCING.....	32
SEQUENCING COSTS.....	32
CHAPTER FIVE: GENE MUTATION DISORDERS	33
DESCRIPTIONS OF GENE MUTATION DISORDERS	33
CYSTIC FIBROSIS	33
Treatment Options	34
Key Products.....	34
<i>TABLE 8 PHARMACEUTICAL TREATMENTS FOR CYSTIC FIBROSIS</i>	34
New Developments.....	34

New Developments (Continued).....	35
<i>TABLE 9 CYSTIC FIBROSIS DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	36
<i>TABLE 9 (CONTINUED)</i>	37
FABRY DISEASE.....	37
Treatment Options	37
Key Products.....	38
<i>TABLE 10 PHARMACEUTICAL TREATMENTS FOR FABRY DISEASE</i>	38
New Developments	38
<i>TABLE 11 FABRY DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	38
GAUCHER'S DISEASE	39
Treatment Options	39
Key Products.....	40
<i>TABLE 12 PHARMACEUTICAL TREATMENTS FOR GAUCHER'S DISEASE</i>	40
New Developments	40
<i>TABLE 13 GAUCHER'S DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	41
HEMOPHILIA AND OTHER INHERITED BLEEDING DISORDERS	41
Treatment Options	41
Key Products.....	41
Key Products (Continued)	42
<i>TABLE 14 BIOLOGICAL AND PHARMACEUTICAL TREATMENTS FOR HEMOPHILIA AND OTHERS</i>	43
<i>TABLE 15 EXPANDED INDICATIONS AND PRODUCT CHANGES 2005-2009</i>	44
New Developments	45
<i>TABLE 16 HEMOPHILIA AND RELATED BLOOD DISORDER DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	46
HUNTINGTON'S DISEASE.....	46
Treatment Options	47
Key Products.....	47
<i>TABLE 17 PHARMACEUTICAL TREATMENTS FOR HUNTINGTON'S DISEASE</i>	47
New Developments	48
<i>TABLE 18 HUNTINGTON'S DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	48
HUNTER SYNDROME.....	48
Treatment Options	49
Key Products.....	49
<i>TABLE 19 PHARMACEUTICAL TREATMENTS FOR HUNTER SYNDROME</i>	49

New Developments	49
<i>TABLE 20 HUNTER SYNDROME DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	<i>50</i>
HURLER SYNDROME	50
Treatment Options	50
Key Products	51
<i>TABLE 21 PHARMACEUTICAL TREATMENTS FOR HURLER SYNDROME</i>	<i>51</i>
New Developments	51
MAROTEAUX–LAMY SYNDROME	51
Treatment Options	51
Key Products	52
<i>TABLE 22 PHARMACEUTICAL TREATMENTS FOR MAROTEAUX–LAMY SYNDROME</i>	<i>52</i>
PHENYLKETONURIA (PKU)	52
Treatment Options	53
Key Products	53
<i>TABLE 23 PHARMACEUTICAL TREATMENTS FOR PKU</i>	<i>53</i>
New Developments	54
<i>TABLE 24 PKU DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	<i>54</i>
POMPE DISEASE	54
Treatment Options	54
Key Products	55
<i>TABLE 25 PHARMACEUTICAL TREATMENTS FOR POMPE DISEASE</i>	<i>55</i>
New Developments	55
<i>TABLE 26 POMPE DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	<i>55</i>
SICKLE CELL DISEASE	55
Treatment Options	56
Key Products	56
<i>TABLE 27 PHARMACEUTICAL TREATMENTS FOR SICKLE CELL DISEASE</i>	<i>57</i>
New Developments	57
<i>TABLE 28 SICKLE CELL DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	<i>57</i>
TAY–SACHS DISEASE	57
Treatment Options	58
Key Products	58
New Developments	58
<i>TABLE 29 TAY–SACHS DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	<i>59</i>
WILSON’S DISEASE	59
Treatment Options	59
Key Products	59

<i>TABLE 30 PHARMACEUTICAL TREATMENTS FOR WILSON'S DISEASE</i>	60
New Developments	60
<i>TABLE 31 WILSON'S DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	61
OTHER APPROVED PRODUCTS FOR RARE GENETIC DISORDERS	61
OTHER NEW DEVELOPMENT PROJECTS	61
PHASE II	61
PHASE I	62
PRECLINICAL.....	62
MUSCULAR DYSTROPHY FOCUS: PRECLINICAL THROUGH PHASE III.....	63
AVI-4658	63
AVI-5038	64
Catena/Sovrima	64
PRO044	64
PTC-124.....	64
SNT-317/omigapil	64
STATISTICS	65
CYSTIC FIBROSIS	65
<i>TABLE 32 CYSTIC FIBROSIS STATISTICS</i>	65
GAUCHER'S DISEASE	65
<i>TABLE 33 GAUCHER'S DISEASE STATISTICS</i>	66
PHENYLKETONURIA	66
TAY-SACHS DISEASE	66
<i>TABLE 34 TAY-SACHS DISEASE STATISTICS</i>	67
SICKLE CELL DISEASE	67
<i>TABLE 35 SICKLE-CELL DISEASE STATISTICS</i>	67
HEMOPHILIA.....	67
HUNTINGTON'S DISEASE.....	68
MARKET SIZE AND GROWTH	68
<i>TABLE 36 GLOBAL GENE MUTATION PRODUCT REVENUES BY DISORDER THROUGH 2014 (\$ MILLIONS)</i>	69
<i>FIGURE 5 GLOBAL GENE MUTATION PRODUCT REVENUES BY DISORDER, 2007-2014 (\$ MILLIONS)</i>	70
COMPETITIVE STRUCTURE AND MARKET SHARE	70
CYSTIC FIBROSIS MARKET.....	70
<i>TABLE 37 GLOBAL PRODUCT REVENUES FOR CYSTIC FIBROSIS TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	71
<i>FIGURE 6 GLOBAL PRODUCT REVENUES FOR CYSTIC FIBROSIS TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	72
FABRY DISEASE MARKET	72

<i>TABLE 38 GLOBAL PRODUCT REVENUES FOR FABRY DISEASE TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	73
<i>FIGURE 7 GLOBAL PRODUCT REVENUES FOR FABRY DISEASE TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	73
GAUCHER'S DISEASE MARKET.....	74
<i>TABLE 39 GLOBAL PRODUCT REVENUES FOR GAUCHER'S DISEASE TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	74
<i>FIGURE 8 GLOBAL PRODUCT REVENUES FOR GAUCHER'S DISEASE TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	75
HEMOPHILIA AND RELATED BLOOD DISORDER MARKET	75
Hemophilia and Related Blood ... (Continued)	76
<i>TABLE 40 GLOBAL PRODUCT REVENUES FOR HEMOPHILIA TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	77
<i>FIGURE 9 GLOBAL PRODUCT REVENUES FOR HEMOPHILIA TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	77
HUNTINGTON'S DISEASE MARKET.....	78
<i>TABLE 41 GLOBAL PRODUCT REVENUES FOR HUNTINGTON'S DISEASE TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	78
<i>FIGURE 10 GLOBAL PRODUCT REVENUES FOR HUNTINGTON'S DISEASE TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	79
HUNTER SYNDROME MARKET	79
<i>TABLE 42 GLOBAL PRODUCT REVENUES FOR HUNTER SYNDROME TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	80
<i>FIGURE 11 GLOBAL PRODUCT REVENUES FOR HUNTER SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	80
HURLER SYNDROME MARKET.....	80
<i>TABLE 43 GLOBAL PRODUCT REVENUES FOR HURLER SYNDROME TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	81
<i>FIGURE 12 GLOBAL PRODUCT REVENUES FOR HURLER SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	81
MAROTEAUX-LAMY SYNDROME MARKET.....	81
<i>TABLE 44 GLOBAL PRODUCT REVENUES FOR MAROTEAUX-LAMY SYNDROME TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	82

<i>FIGURE 13 GLOBAL PRODUCT REVENUES FOR MAROTEAUX-LAMY SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	82
PHENYLKETONURIA (PKU) MARKET	83
<i>TABLE 45 GLOBAL PRODUCT REVENUES FOR PKU TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	83
<i>FIGURE 14 GLOBAL PRODUCT REVENUES FOR PKU TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	83
POMPE DISEASE MARKET	84
<i>TABLE 46 GLOBAL PRODUCT REVENUES FOR POMPE DISEASE TREATMENTS BY MANUFACTURER, THROUGH 2014 (\$ MILLIONS)</i>	84
<i>FIGURE 15 GLOBAL PRODUCT REVENUES FOR POMPE DISEASE TREATMENTS BY MANUFACTURER, 2007-2014 (\$ MILLIONS)</i>	84
CHAPTER SIX: CHROMOSOMAL DISORDERS	85
DESCRIPTIONS OF CHROMOSOMAL DISORDERS.....	85
DOWN SYNDROME.....	85
Treatment Options	85
New Developments	86
<i>TABLE 47 DOWN SYNDROME DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	86
KLINFELTER SYNDROME.....	86
Treatment Options	87
Key Products.....	87
<i>TABLE 48 EXAMPLES OF PHARMACEUTICAL TREATMENTS FOR KLINFELTER SYNDROME</i>	87
New Developments	88
<i>TABLE 49 EXAMPLES OF TESTOSTERONE REPLACEMENT DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	88
PRADER-WILLI SYNDROME	88
Treatment Options	88
Key Products.....	89
<i>TABLE 50 PHARMACEUTICAL TREATMENTS FOR PRADER-WILLI SYNDROME</i>	89
New Developments	89
TURNER SYNDROME.....	90
Treatment Options	90
Key Products.....	91
<i>TABLE 51 FDA APPROVED BIOPHARMACEUTICAL TREATMENTS FOR TURNER'S SYNDROME</i>	92
<i>TABLE 51 (CONTINUED)</i>	93
New Developments	93
<i>TABLE 52 TURNER SYNDROME DEVELOPMENTS BY PHASE OF DEVELOPMENT</i>	93

STATISTICS	93
DOWN SYNDROME	93
<i>TABLE 53 DOWN SYNDROME RISK AS A COMPARISON TO</i>	
<i>MATERNAL AGE</i>	94
KLINEFELTER SYNDROME	94
PRADER–WILLI SYNDROME	94
TURNER SYNDROME	94
MARKET SIZE AND GROWTH	94
<i>TABLE 54 GLOBAL CHROMOSOMAL DISORDER PRODUCT</i>	
<i>REVENUES* BY DISORDER, THROUGH 2014 (\$ MILLIONS)</i>	95
<i>FIGURE 16 GLOBAL CHROMOSOMAL DISORDER PRODUCT</i>	
<i>REVENUES BY DISORDER, 2007-2014 (\$ MILLIONS)</i>	95
COMPETITIVE STRUCTURE AND MARKET SHARE	96
KLINEFELTER SYNDROME	96
<i>TABLE 55 GLOBAL PRODUCT REVENUES FOR KLINEFELTER</i>	
<i>SYNDROME TREATMENTS, THROUGH 2014 (\$ MILLIONS)</i>	96
<i>FIGURE 17 GLOBAL PRODUCT REVENUES FOR KLINEFELTER</i>	
<i>SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 (\$</i>	
<i>MILLIONS)</i>	97
PRADER–WILLI SYNDROME	97
<i>TABLE 56 GLOBAL PRODUCT REVENUES* FOR PRADER–WILLI</i>	
<i>SYNDROME TREATMENTS BY MANUFACTURER, THROUGH</i>	
<i>2014 (\$ MILLIONS)</i>	98
<i>FIGURE 18 GLOBAL PRODUCT REVENUES FOR PRADER–WILLI</i>	
<i>SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 (\$</i>	
<i>MILLIONS)</i>	98
TURNER’S SYNDROME	98
<i>TABLE 57 GLOBAL PRODUCT REVENUES* FOR TURNER’S</i>	
<i>SYNDROME TREATMENTS BY MANUFACTURER, THROUGH</i>	
<i>2014 (\$ MILLIONS)</i>	99
<i>FIGURE 19 GLOBAL PRODUCT REVENUES FOR TURNER’S</i>	
<i>SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 (\$</i>	
<i>MILLIONS)</i>	100
CHAPTER SEVEN: MARKET SUMMARY	101
TOTAL GLOBAL MARKET FOR GENETIC DISORDERS	101
<i>TABLE 58 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY</i>	
<i>MAJOR MARKET SEGMENT, THROUGH 2014 (\$ MILLIONS)</i>	101
<i>FIGURE 20 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY</i>	
<i>MAJOR MARKET SEGMENT, 2007-2014 (\$ MILLIONS)</i>	102
TOTAL GLOBAL MARKET AND PERCENT DISTRIBUTION BY	
SELECTED GENETIC DISORDER	102
<i>TABLE 59 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY</i>	
<i>DISORDER THROUGH 2014 (\$ MILLIONS)</i>	103

FIGURE 21 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY DISORDER, 2007-2014 (\$ MILLIONS).....	104
GEOGRAPHICAL ANALYSIS OF GENETIC DISORDER TREATMENTS	104
TABLE 60 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY SELECTED COUNTRY, THROUGH 2014 (\$ MILLIONS).....	105
FIGURE 22 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY SELECTED COUNTRY, 2007-2014 (\$ MILLIONS).....	106
MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT	106
MAJOR INDUSTRY PARTICIPANTS ...(CONTINUED)	107
TABLE 61 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENTS AND SALES GROWTH, THROUGH 2014 (\$ MILLIONS).....	108
TABLE 61 (CONTINUED).....	109
CHAPTER EIGHT: TECHNOLOGY	110
PATENT ANALYSIS	110
PATENTS AND GENETICS	110
PATENT EVALUATION BY GENETIC CONDITION	111
TABLE 62 PATENT INFORMATION BY GENETIC CONDITION	112
TABLE 62 (CONTINUED).....	113
TABLE 62 (CONTINUED).....	114
TABLE 62 (CONTINUED).....	115
TABLE 62 (CONTINUED).....	116
FIGURE 23 PERCENT OF PATENTS BY GENETIC CONDITION (%)	116
FIGURE 23 (CONTINUED)	117
PATENT EVALUATION BY ASSIGNEE.....	117
TABLE 63 GENETIC PATENT ASSIGNEES.....	117
TABLE 63 (CONTINUED).....	118
TABLE 63 (CONTINUED).....	119
Bristol-Myers Squibb	120
Eli Lilly	120
G. D. Searle & Co./Monsanto Company.....	120
Genzyme Corp.....	120
Purdue Pharma	120
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.....	121
Transkaryotic Therapies	121
Wyeth	121
CHAPTER NINE: COMPANY PROFILES	122
BAXTER INTERNATIONAL, INC.	122
TABLE 64 BAXTER'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS).....	123
FIGURE 24 BAXTER'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS).....	124
BAYER AG	124

<i>TABLE 65 BAYER'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS).....</i>	<i>125</i>
<i>FIGURE 25 BAYER'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS)....</i>	<i>126</i>
BIOMARIN PHARMACEUTICAL, INC.....	126
<i>TABLE 66 BIOMARIN'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>127</i>
<i>FIGURE 26 BIOMARIN'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>127</i>
CANGENE CORP.	128
<i>TABLE 67 CANGENE'S COMPANY REVENUES, 2007-2009* (\$</i>	
<i>MILLIONS).....</i>	<i>129</i>
<i>FIGURE 27 CANGENE'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>129</i>
CSL BEHRING (CSL LIMITED)	129
<i>TABLE 68 CSL'S COMPANY REVENUES, 2007-2009* (\$ MILLIONS)</i>	<i>130</i>
<i>FIGURE 28 CSL'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS).....</i>	<i>130</i>
ELI LILLY.....	131
<i>TABLE 69 ELI LILLY'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>131</i>
<i>FIGURE 29 ELI LILLY'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>132</i>
ENDO PHARMACEUTICALS	132
<i>TABLE 70 ENDO'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS).....</i>	<i>133</i>
<i>FIGURE 30 ENDO'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS)</i>	<i>134</i>
GENENTECH INC.	134
<i>TABLE 71 GENENTECH AND ROCHE COMPANY REVENUES, 2007-</i>	
<i>2009 (\$ MILLIONS).....</i>	<i>135</i>
<i>FIGURE 31 GENENTECH AND ROCHE COMPANY REVENUES, 2007-</i>	
<i>2009 (\$ MILLIONS).....</i>	<i>135</i>
GENZYME	135
<i>TABLE 72 GENZYME'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>136</i>
<i>FIGURE 32 GENZYME'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>137</i>
H. LUNDBECK A/S	137
<i>TABLE 73 LUNDBECK'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>138</i>
<i>FIGURE 33 LUNDBECK'S COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>138</i>
NOVARTIS INTERNATIONAL AG/SANDOZ	138
NOVARTIS INTERNATIONAL AG/... (CONTINUED).....	139
<i>TABLE 74 NOVARTIS' COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>140</i>
<i>FIGURE 34 NOVARTIS' COMPANY REVENUES, 2007-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>140</i>

NOVO NORDISK A/S.....	140
<i>TABLE 75 NOVO NORDISK'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS)</i>	141
<i>FIGURE 35 NOVO NORDISK'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS)</i>	141
PFIZER, INC/WYETH.....	142
<i>TABLE 76 PFIZER'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS)</i>	143
<i>FIGURE 36 PFIZER'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS)</i>	143
SHIRE PLC	143
<i>TABLE 77 SHIRE'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS)</i>	144
<i>FIGURE 37 SHIRE'S COMPANY REVENUES, 2007-2009 (\$ MILLIONS)</i>	144

APPENDIX I: COMPANIES WITH GENETIC RESEARCH PROJECTS	145
ADEONA PHARMACEUTICALS, INC.	145
AEROVANCE, INC.....	145
ALDAGEN, INC.....	145
AMICUS THERAPEUTICS, INC.....	145
AOP ORPHAN PHARMACEUTICALS AG.....	145
APPLIED GENETIC TECHNOLOGIES CORP.....	145
AVI BIOPHARMA	145
AVICENA GROUP, INC.....	146
BAYER SCHERING PHARMA AG.....	146
BIOGEN IDEC.....	146
BIOMARIN PHARMACEUTICAL INC.....	146
COPERNICUS THERAPEUTICS, INC.....	146
CSL BEHRING	146
EISAI, INC.....	146
GILEAD SCIENCES, INC.....	147
GLAXOSMITHKLINE PLC	147
HOLLIS-EDEN PHARMACEUTICALS, INC.	147
INSPIRE PHARMACEUTICALS, INC.....	147
IPSEN.....	147
KALOBIOS PHARMACEUTICALS, INC.....	147
LANTIBIO, INC.....	147
MPEX PHARMACEUTICALS, INC.	148
NEUROSEARCH A/S	148
NORTHFIELD LABORATORIES, INC.....	148
NOVO NORDISK A/S.....	148
PFIZER, INC.....	148
PHARMAXIS LTD	148
PROSENSA HOLDING B.V.....	149
PROTALIX BIOTHERAPEUTICS	149
PTC THERAPEUTICS, INC.	149
QUATRUX PHARMACEUTICALS	149

REGENERX BIOPHARMACEUTICALS, INC.	149
REPROS THERAPEUTICS INC.....	149
SANTHERA PHARMACEUTICALS HOLDING AG.....	150
SHIRE PLC	150
SUCAMPO PHARMACEUTICALS, INC.	150
TRANSAVE, INC.....	150
VERTEX PHARMACEUTICALS, INC.	150
APPENDIX II: ASSOCIATIONS AND ORGANIZATIONS.....	151
ANGELMAN SYNDROME FOUNDATION, INC.....	151
CANADIAN SOCIETY FOR MUCOPOLYSACCHARIDE AND RELATED DISEASES, INC.....	151
CHILDREN LIVING WITH INHERITED METABOLIC DISEASES (CLIMB)	152
CELIAC DISEASE FOUNDATION.....	152
CELIAC SPRUE ASSOCIATION.....	152
CURE CMD (CONGENITAL MUSCULAR DYSTROPHY).....	152
CYSTIC FIBROSIS FOUNDATION	152
CYSTIC FIBROSIS RESEARCH, INC.	152
CYSTIC FIBROSIS TRUST	153
CYSTIC FIBROSIS WORLDWIDE.....	153
DOWN'S SYNDROME ASSOCIATION (UK).....	153
FABRY SUPPORT & INFORMATION GROUP	153
GAUCHERS ASSOCIATION (UK)	153
HIDE & SEEK FOUNDATION FOR LYSOSOMAL DISEASE RESEARCH	153
HEMOPHILIA FEDERATION OF AMERICA.....	154
HUNTINGTON'S ASSOCIATION OF SOUTH AFRICA POSTBOX 4640	154
HUNTINGTON'S DISEASE SOCIETY OF AMERICA	154
HUNTINGTON SOCIETY OF CANADA	154
INTERNATIONAL CENTER FOR FABRY DISEASE	154
INSTITUTO DE ERRORES INNATOS DEL METABOLISMO.....	155
KLINEFELTER SYNDROME & ASSOCIATES (KS&A)	155
MARCH OF DIMES BIRTH DEFECTS FOUNDATION	155
MUSCULAR DYSTROPHY ASSOCIATION.....	155
MUSCULAR DYSTROPHY LIMITED (AUSTRALIA)	155
MUSCULAR DYSTROPHY ASSOCIATION OF NEW ZEALAND, INC.....	155
MUSCULAR DYSTROPHY CAMPAIGN.....	156
MUSCULAR DYSTROPHY CANADA.....	156
MUSCULAR DYSTROPHY IRELAND	156
NATIONAL FOUNDATION FOR CELIAC AWARENESS (NFCA)	156
NATIONAL GAUCHER'S FOUNDATION.....	156
NATIONAL HEMOPHILIA FOUNDATION.....	156

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS)	157
NATIONAL MPS SOCIETY (HUNTER SYNDROME)	157
NATIONAL MPS (MUCOPOLYSACCHARIDOSES/ MUCOLIPIDOSES) SOCIETY, INC.	157
NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD).....	157
NATIONAL TAY–SACHS AND ALLIED DISEASES ASSOCIATION, INC.	157
PRADER–WILLI SYNDROME ASSOCIATION (UK)	158
THE PRADER–WILLI SYNDROME ASSOCIATION (USA)	158
SICKLE CELL ASSOCIATION	158
SICKLE CELL ASSOCIATION OF ONTARIO	158
SICKLE CELL ASSOCIATION OF TEXAS GULF COAST	158
SICKLE CELL DISEASE ASSOCIATION OF PIEDMONT.....	158
SICKLE CELL DISEASE FOUNDATION OF CALIFORNIA.....	158
SOCIETY FOR MUSCULAR DYSTROPHY INFORMATION INTERNATIONAL	159
TURNER'S SYNDROME SOCIETY	159
TURNER SYNDROME SUPPORT SOCIETY (UK)	159
U.S. NATIONAL LIBRARY OF MEDICINE.....	159
 APPENDIX III: INTERNATIONAL LOCATIONS OF GENETIC CLINICS	 160
ARGENTINA.....	160
AUSTRALIA.....	160
AUSTRIA.....	161
BAHRAIN.....	161
BELGIUM	161
BRAZIL.....	162
CANADA	162
CHILE	163
CZECH REPUBLIC	163
DENMARK.....	163
FRANCE.....	163
GERMANY.....	164
GREECE.....	164
INDIA	164
ISRAEL.....	164
ITALY	165
JAPAN.....	165
NETHERLANDS	165
NEW ZEALAND	166
PORTUGAL.....	166
RUSSIA	166
SAUDI ARABIA	166
SOUTH KOREA.....	166

SPAIN..... 167
TURKEY..... 167
UNITED KINGDOM..... 167